Acumen Pharmaceuticals Résultats passés
Passé contrôle des critères 0/6
Acumen Pharmaceuticals's earnings have been declining at an average annual rate of -8.5%, while the Biotechs industry saw earnings growing at 19% annually. Revenues have been declining at an average rate of 164.7% per year.
Informations clés
-8.5%
Taux de croissance des bénéfices
75.5%
Taux de croissance du BPA
Biotechs Croissance de l'industrie | 17.0% |
Taux de croissance des recettes | -164.7% |
Rendement des fonds propres | -26.6% |
Marge nette | n/a |
Dernière mise à jour des bénéfices | 30 Jun 2024 |
Mises à jour récentes des performances passées
Recent updates
Does Acumen Pharmaceuticals (NASDAQ:ABOS) Have A Healthy Balance Sheet?
Aug 05Acumen Pharmaceuticals: Healthy Cash Runway And Market Potential In Alzheimer's
Jul 30Is Acumen Pharmaceuticals (NASDAQ:ABOS) Weighed On By Its Debt Load?
Apr 21Companies Like Acumen Pharmaceuticals (NASDAQ:ABOS) Are In A Position To Invest In Growth
Sep 21We're Not Very Worried About Acumen Pharmaceuticals' (NASDAQ:ABOS) Cash Burn Rate
Feb 01Acumen Pharmaceuticals (NASDAQ:ABOS) Is In A Good Position To Deliver On Growth Plans
Oct 16Acumen Pharma at 11-month high on rivals’ Alzheimer’s data
Sep 28Acumen Pharmaceuticals initiated at buy at H.C. Wainwright on Alzheimer's candidate
Jun 30We Think Acumen Pharmaceuticals (NASDAQ:ABOS) Can Afford To Drive Business Growth
May 10We're Not Very Worried About Acumen Pharmaceuticals' (NASDAQ:ABOS) Cash Burn Rate
Jan 07Acumen Pharmaceuticals (NASDAQ:ABOS) Is In A Good Position To Deliver On Growth Plans
Oct 01Ventilation des recettes et des dépenses
Comment Acumen Pharmaceuticals gagne et dépense de l'argent. Sur la base des derniers bénéfices déclarés, sur une base LTM.
Historique des gains et des recettes
Date | Recettes | Les revenus | Dépenses G+A | Dépenses de R&D |
---|---|---|---|---|
30 Jun 24 | 0 | -65 | 20 | 0 |
31 Mar 24 | 0 | -56 | 20 | 0 |
31 Dec 23 | 0 | -52 | 19 | 0 |
30 Sep 23 | 0 | -49 | 17 | 0 |
30 Jun 23 | 0 | -46 | 15 | 0 |
31 Mar 23 | 0 | -45 | 14 | 0 |
31 Dec 22 | 0 | -43 | 13 | 0 |
30 Sep 22 | 0 | -38 | 12 | 0 |
30 Jun 22 | 0 | -32 | 11 | 0 |
31 Mar 22 | 0 | -83 | 9 | 0 |
31 Dec 21 | 0 | -101 | 7 | 0 |
30 Sep 21 | 0 | -93 | 5 | 0 |
30 Jun 21 | 1 | -92 | 3 | 0 |
31 Mar 21 | 1 | -32 | 2 | 0 |
31 Dec 20 | 1 | -7 | 1 | 0 |
31 Dec 19 | 2 | -8 | 1 | 0 |
Des revenus de qualité: ABOS is currently unprofitable.
Augmentation de la marge bénéficiaire: ABOS is currently unprofitable.
Analyse des flux de trésorerie disponibles par rapport aux bénéfices
Analyse de la croissance passée des bénéfices
Tendance des revenus: ABOS is unprofitable, and losses have increased over the past 5 years at a rate of 8.5% per year.
Accélération de la croissance: Unable to compare ABOS's earnings growth over the past year to its 5-year average as it is currently unprofitable
Bénéfices par rapport au secteur d'activité: ABOS is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (-2.3%).
Rendement des fonds propres
ROE élevé: ABOS has a negative Return on Equity (-26.59%), as it is currently unprofitable.